Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) University of Vermont |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00000231 |
The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with pro-social activities. In addition, we will examine whether blind naltrexone dosing is effective in indicating naltrexone consumption.
Condition | Intervention | Phase |
---|---|---|
Opioid-Related Disorders |
Drug: Buprenorphine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Buprenorphine Detoxification With Two Types of Treatment. BBD IV |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Please contact site for information.
United States, Vermont | |
Treatment Research Center | |
Burlington, Vermont, United States, 05401 |
Principal Investigator: | Warren Bickel, Ph.D. | University of Vermont |
Study ID Numbers: | NIDA-06969-13, R01-06969-13 |
Study First Received: | September 20, 1999 |
Last Updated: | August 16, 2005 |
ClinicalTrials.gov Identifier: | NCT00000231 |
Health Authority: | United States: Federal Government |
Buprenorphine Mental Disorders Substance-Related Disorders Disorders of Environmental Origin Opioid-Related Disorders |
Sensory System Agents Therapeutic Uses Narcotic Antagonists Physiological Effects of Drugs Central Nervous System Depressants Narcotics |
Peripheral Nervous System Agents Analgesics Central Nervous System Agents Pharmacologic Actions Analgesics, Opioid |